- 1 **Title:** Comparative Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults
- 2 **Authors:** Seon Kyeong Park^{1*}, Young June Choe^{2*}, Seung Ah Choe³, Benjamin John Cowling⁴,
- 3 Ji Hae Hwang¹, Ju Hee Lee¹, Kil Hun Lee¹, Seonju Yi¹, Sang Won Lee¹, Geun-Yong Kwon¹, Eun
- 4 Jung Jang¹, Ryu Kyung Kim¹, Young-Joon Park¹
- 5 *Equally contributed to the manuscript
- 6 Affiliations: ¹Director for Epidemiological Investigation Analysis, Korea Disease Control and
- 7 Prevention Agency, Cheongju, Korea; ²Department of Pediatrics, Korea University Anam
- 8 Hospital, and Allergy and Immunology Center, Korea University, Seoul, Korea; ³Department of
- 9 Preventive Medicine, Korea University College of Medicine, Seoul, Korea; ⁴WHO Collaborating
- 10 Centre for Infectious Disease Epidemiology and Control, School of Public Health, The
- 11 University of Hong Kong, Pokfulam, Hong Kong
- 12 **Correspondence:** Young-Joon Park, MD, MPH. Director for Epidemiological Investigation
- 13 Analysis, Korea Disease Control and Prevention Agency, Osong Health Technology
- 14 Administration Complex, 187 Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju
- 15 28159, Korea. Email: pahmun@korea.kr
- 16 **Key points:** COVID-19; Korea; SARS-CoV-2; vaccine effectiveness; BNT162b2; NVX-
- 17 CoV2373

19

20

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Abstract Background: Various types of vaccines against SARS-CoV-2 have reduced the burden of coronavirus diseases 2019 (COVID-19) across the world. We conducted an observational study to evaluate the effectiveness of NVX-CoV2373 and BNT162b2 in providing protection in Korean adults. **Methods:** This study was a retrospective matched cohort study to emulate a target trial of three doses of NVX-CoV2373 (N-N-N) versus three doses of BNT162b2 (B-B-B) vaccines in presumed immune-naive adults. We used data from the Korea COVID-19 Vaccine Effectiveness (K-COVE) cohort, combining all COVID-19 laboratory-confirmed cases and all COVID-19 immunization registry, between February and November 2022. We calculated 40-week risk differences and risk ratios between the two vaccines. Results: A total of 3,019 recipients of NVX-CoV2373 vaccine and 3,027 recipients of BNT162b2 vaccine were eligible for the study. The 40-week risk ratios for recipients of the NVX-CoV2373 vaccine as compared with recipients of the BNT162b2 vaccine were 1.169 (95% CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection, and 0.504 (95% CI, 0.126 to 2.014) for severe SARS-CoV-2 infection. Estimated risk of severe infection was 0.001 events per 1000 persons (95% CI, 0 to 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000 persons (95% CI, 0.001 to 0.006) for BNT162b2 vaccine. Conclusion: This study identifies reduced risk of SARS-CoV-2 infection and severe infection after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean adults.

1	Direct, vaccine-conferred protection may be of importance among high risk persons to mitigate
12	from serious clinical outcome from COVID-19.
13	
14	
15	
16	
17	
18	
19	
50	
51	
52	
53	
54	
55	
66	
57	
58	

Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Various types of vaccines against SARS-CoV-2 have reduced the burden of coronavirus diseases 2019 (COVID-19) across the world [1]. However, global problem with supply and ongoing demand for booster doses of COVID-19 vaccines makes large portion of population under-immunized [2]. Moreover, allergic reaction to certain types of vaccines calls upon the medical needs for other options to prevent from severe COVID-19 [3, 4]. The recombinant protein-based vaccine NVX-CoV2373 has demonstrated high immunogenicity and efficacy against COVID-19 and has been introduced in more than 40 countries [5, 6]. Despite its use in different settings, the comparative effectiveness of NVX-CoV2373 and other COVID-19 vaccines for the prevention of SARS-CoV-2 infection has yet to be assessed. Since the beginning of COVID-19 pandemic, South Korean government has been operating a centralized public health database that collects all reported COVID-19 cases and their vaccination status [7]. The NVX-CoV2373 vaccine was introduced in South Korea on March 2022, and as of February 2023, more than 300,000 doses have been distributed [8]. With real-time vaccine registry merged with COVID-19 surveillance data, there is an opportunity to assess the comparative effectiveness of NVX-CoV2373 vaccine [9, 10]. Herein, we conducted an observational study in which we evaluated the effectiveness of NVX-CoV2373 and BNT162b2 in providing protection against SARS-CoV-2 infection and severe infection in Korean adults.

Methods

This study was a retrospective matched cohort study to emulate a target trial of three doses of NVX-CoV2373 (N-N-N) versus three doses of BNT162b2 (B-B-B) vaccines in presumed immune-naive adults. We used data from the Korea COVID-19 Vaccine Effectiveness (K-COVE) cohort, a large-linked database combining all COVID-19 laboratory-confirmed cases and all COVID-19 immunization registry in South Korea. Detailed information about the K-COVE cohort has been published previously [11-13].

In current study, 4,547,432 Korean adults ≥18 yrs. of age without a previously documented SARS-CoV-2 infection or COVID-19 vaccination, as of February 14, 2022, were initially screened. Eligibility criteria included all Korean nationals aged at least 18 years, no previously documented SARS-CoV-2 infection, and has had three doses of NVX-CoV2373 or BNT162b2 vaccines between February 14 and November 26, 2022 (286 days). Matching criteria included age, sex, geographic region, and health status (immunocompromised vs. not). The detailed case selection flow is shown in Figure 1.

The interventions of interest were the third-dose vaccination with NVX-CoV2373 vaccine (after receipt of two doses of NVX-CoV2373) or the third-dose of BNT162b2 vaccine (after receipt of two doses of BNT162b2). Between February and November 2022, there was no preferential recommendation issued by the government or academic society between NVX-CoV2373 or BNT162b2 vaccines, and all persons aged 12 years and above were eligible for free vaccination during this period. Per national guideline, both NVX-CoV2373 BNT162b2 vaccine's schedules were as follows: two doses in interval of 3 weeks; followed by a third dose booster after 3 months, and a fourth dose booster after 4 months. The third dose booster vaccination was

recommended for all adults aged 18 years and above; while the forth dose booster vaccination was first recommended to immunocompromised patients (18-49 years) and adults aged 50 years and above, but was opened to all adults who were willing to get vaccinated. Per national guideline, booster series with homologous vaccine type was recommended (i.e., N-N-N or B-B-B).

The two outcomes of interest were (1) laboratory-confirmed SARS-CoV-2 infection, and (2) severe SARS-CoV-2 infection. Laboratory-confirmed SARS-CoV-2 infection include either rapid antigen test (RAT) and polymerase chain reaction (PCR) test, conducted by healthcare professionals. Severe SARS-CoV-2 infection is defined if the patient was treated with high flow oxygen, invasive mechanical ventilation, extracorporeal membrane oxygenation, continuous renal replacement therapy, or death attributable to COVID-19, within 30 days following diagnosis of COVID-19.

For each eligible participant, follow-up started on the day the first dose of vaccine was received and ended on the day of the outcome of interest or the end of the study, whichever occurred first. Observed period was from February 14, 2022, to November 26, 2022 for SARS-CoV-2 infection; and for severe infection, the observed period was extended through December 24, 2022. Supplemental Figure 1 shows the trend of national virus genomic surveillance data suggesting that BA.2, BA.2.3., and BA.5 were the main circulating subvariant during the observed period.

We used the Kaplan-Meier estimator with daily outcome events to compute the risk of the outcome during the period, then calculated 40-week risk differences and risk ratios between the NVX-CoV2373 and BNT162b2 groups. Statistical analyses were conducted using R v.4.02 (R Core Team, Vienna, Austria).

This study was conducted as a legally mandated public health investigation under the authority of the Korean Infectious Diseases Control and Prevention Act. The study was approved by the Korea Disease Control and Prevention Agency Institutional Review Board (IRB No. 2021-12-03-PE-A).

Results

Among the 14,325 Korean adults who received their third dose of NVX-CoV2373 or BNT162b2 vaccines after February 14, 2022, a total of 3,019 recipients of NVX-CoV2373 vaccine and 3,027 recipients of BNT162b2 vaccine were eligible for the study (Figure 1). The baseline characteristics of matched persons is shown in Table 1. The median age was 54 years in both groups, female-to-male ratio was 55:45, and 0.1%-0.2% were long-term care facility residents, and 7.4%-7.5% were immunocompromised patients. The median follow-up period was 97.19 days for NVX-CoV2373 recipients and 97.61 days for BNT162b2 recipients. Supplementary Table 1 shows the characteristics of unmatched NVX-CoV2373 recipients, and Supplementary Table 2 shows the characteristics of unvaccinated, 1-dose vaccinated, 2-dose vaccinated, and those who received heterologous booster 3-doses.

Over a 40-week follow-up period, there were 769 SARS-CoV-2 laboratory-confirmed infection and of those, nine cases (1.1 %) were classified as severe infection (Table 2). Of the 413 laboratory-confirmed-infection among NVX-CoV2373 recipients, three cases (0.7%) were

classified as severe infection; while of the 356 laboratory-confirmed-infection among BNT162b2 recipients, six (1.7%) were classified as severe infection. The 40-week risk ratios for recipients of the NVX-CoV2373 vaccine as compared with recipients of the BNT162b2 vaccine were 1.169 (95% CI, 1.015 to 1.347) for laboratory-confirmed SARS-CoV-2 infection, and 0.504 (95% CI, 0.126 to 2.014) for severe SARS-CoV-2 infection (Table 2). The risk differences (BNT162b2 minus NVX-CoV2373), expressed as events over 40 weeks per 1,000 persons, were 1.214 (95% CI, 1.083 to 1.337) for laboratory-confirmed SARS-CoV-2 infection, and 0.020 (95% CI, 0.007 to 0.044) for severe infection. Supplementary Table 3 shows age-specific risk ratio and risk difference.

Figure 1 shows the cumulative incidence curves for the study outcomes in each vaccine groups. The absolute risks of the outcomes were low in both groups, with estimated risk of all laboratory-confirmed infection was 0.162 events per 1000 persons (95% CI, 0.147 to 0.178) for the NVX-CoV2373 vaccine and 0.140 events per 1000 persons (95% CI, 0.126 to 0.155) for BNT162b2 vaccine. Estimated risk of severe infection was 0.001 events per 1000 persons (95% CI, 0.003) for the NVX-CoV2373 vaccine and 0.002 events per 1000 persons (95% CI, 0.001 to 0.006) for BNT162b2 vaccine.

Discussion

The target trial emulation study we performed in the South Korea demonstrated that the three-dose BNT162b2 had lower risk of all laboratory-confirmed infection compared to NVX-CoV2373, however, the risk of severe infection was similarly low in both vaccines. Our finding

provides strong support for the current indication and recommendation that NVX-CoV2373 provide robust effectiveness against COVID-19 and its serious outcome. Also, the result is in line with previous meta-analysis that pooled 57 studies that showed vaccine effectiveness of 77.1%-98.0% and 86.3%-93.6% for BNT162b2 and NVX-CoV2373 vaccines against SARS-CoV-2 infection, respectively [14]. An Australian study that compared rates of SARS-CoV-2 Omicron BA.1/2 infection showed an adjusted hazard ratio for SARS-CoV-2 infection of NVX-CoV2373 recipients compared to BNT162b2 vaccine was 1.70 (1.46-1.97) [15]. These findings may be related to NVX-CoV2373 vaccine's less inducing of spike-specific CD8 T cells compared to mRNA vaccines, as demonstrated in a German immunogenicity study [16].

Despite the difference in protection against all SARS-CoV-2 infection between the two vaccines, our finding suggests a comparable protective effect against severe infection in both NVX-CoV2373 and BNT162b2 vaccines. A recent randomized trial from the U.S. and Mexico showed the vaccine efficacy of NVX-CoV2373 against moderate-to-severe COVID-19 of 100%, which is in line with our finding [17]. Other immunologic data supports the result we present. A comparative immunogenicity study with BNT162b2 or mRNA-1273 showed that the NVX-CoV2373 have strongly induced spike-specific antibodies and the CD4 T-cells equally recognized all tested variants from Alpha to Omicron [16], which is further supported by a data showing NVX-CoV2373 inducing high functional T-cell immunity [18]. Together with the real-world data that we present, these findings suggest a robust evidence that NVX-CoV2373 provides enhanced protection against severe disease caused by SARS-CoV-2.

The observed period was predominated by the Omicron BA.1, BA.2, and BA.4/5 variants, therefore, our finding suggests a net benefit from the predecessor vaccine with original

strain in mitigating from serious health outcome from SARS-CoV-2 variant [19, 20]. A study evaluating immunogenicity of fourth homologous dose of NVX-CoV2373 showed an enhanced cross-reactive immunity to SARS-CoV-2 variants, suggesting broader protection against emerging SARS-CoV-2 variants [21]. These findings suggest that under current level of circulation of Omicron BA.5 subvariant and in the context of primary immunization with monovalent COVID-19 vaccines, receipt of booster doses may substantially reduce the disease burden in adult population. The homologous booster dose of NVX-CoV2373 vaccine in a phase 2 trial suggested a robust immunogenicity of IgG geometric mean titers (GMT) increased of more than 4-folds against ancestral SARS-CoV-2 strain [22]. In the current study, we only included those who were vaccinated with all three doses of NVX-CoV2373, however, a further study is needed to assess the effectiveness of heterologous vaccination with other types of vaccines. One study that measured heterologous NVX-CoV2373 booster vaccination showed enhanced cross-reactive immunity against Omicron BA.1/BA.5 subvariants [23].

.This study has limitations. First, our finding does not account for potential changes over time in indirect protection as a result of change in population immunity from natural infection but this should not have a differential effect on recipients of NVX-CoV2373 or BNT162b2. Second, we were unable to examine comorbidities and other unmeasured socioeconomic factors and their impact on choice of vaccination or risk of infection, and our results might therefore suffer from confounding. Lastly, SARS-CoV-2 genotypes in individual breakthrough cases were unknown, which may limit the interpretation of our results. Despite these limitations, a key strength of this study is that it showed NVX-CoV2373 vaccine's effectiveness in a large scale of population, including population with an increased risk of COVID-19. Long-term follow-up ins

planned to compare the results in NVX-CoV2373 recipients with those who received other vaccines. In conclusion, our study identifies reduced risk of SARS-CoV-2 infection and severe infection after receipt of three doses of either NVX-CoV2373 or BNT162b2 vaccines in Korean adults. Direct, vaccine-conferred protection may be of importance among high risk persons to mitigate from serious clinical outcome from COVID-19. Updated assessments of the vaccine effectiveness of other COVID-19 vaccines are warranted in light of real-world evidence of vaccine direct effects against evolving variants of SARS-CoV-2.

Acknowledgement: We thank the K-COVE data team for their roles in developing and managing the datasets. We also thank Dr. Mark Thompson and Dr. Muruga Vadivale (both from Novavax Inc.) for advice and feedback in developing this study. Data is not publicly available. Author contribution: Conceived and designed the analyses: S.K.P., Y.J.C., Y.J.P., Performed data extraction and analyzed data: S.K.P., H.H., J.H.L., K.H.L., Data curation and project management: S.Y., G.Y.K., E.J.J., R.K.K., Contributed to analysis: Y.J.C., S.A.C., B.J.C., Y.J.P., Wrote the paper: S.K.P., Y.J.C., Y.J.P. **Funding:** None

Figure legends Figure 1. Selection of Persons for the Emulation of a Target Trial Evaluating the Comparative Effectiveness of the NVX-CoV2373 and BNT162b2 Vaccines during a Period Marked by SARS-CoV-2 Omicron-Variant Predominance (February - November, 2022). Figure 2. Cumulative Incidence of COVID-19 Outcomes during a Period Marked by SARS-CoV-2 Omicron-Variant Predominance (February- November, 2022). Supplementary Figure 1. SARS-CoV-2 subvariants by surveillance week

265 266 267 268 References 269 1. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the 270 first year of COVID-19 vaccination: a mathematical modelling study. The Lancet 271 Infectious diseases **2022**; 22(9): 1293-302. 272 The Lancet Infectious D. COVID-19 vaccine equity and booster doses. The Lancet 2. 273 Infectious diseases **2021**; 21(9): 1193. 274 Blumenthal KG, Robinson LB, Camargo CA, Jr., et al. Acute Allergic Reactions to 3. 275 mRNA COVID-19 Vaccines. Jama 2021; 325(15): 1562-5. 276 4. Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-277 CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, 278 Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy 279 Clin Immunol Pract **2021**; 9(10): 3546-67. 280 Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 5. 281 Vaccine. The New England journal of medicine **2021**; 385(13): 1172-83. 282 6. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike 283 Protein Nanoparticle Vaccine. The New England journal of medicine 2020; 383(24): 284 2320-32.

- 285 7. Yoo KJ, Kwon S, Choi Y, Bishai DM. Systematic assessment of South Korea's
- capabilities to control COVID-19. Health Policy **2021**; 125(5): 568-76.
- 287 8. Central Disease Control headquarters. COVID-19 Vaccination. Accessed at
- https://ncv.kdca.go.kr/eng/; Accessed on: February 14, 2023.
- 289 9. Kwon SL, Oh J. COVID-19 vaccination program in South Korea: A long journey toward
- a new normal. Health policy and technology **2022**; 11(2): 100601.
- 291 10. Yi S, Choe YJ, Lim DS, et al. Impact of national Covid-19 vaccination Campaign, South
- 292 Korea. Vaccine **2022**; 40(26): 3670-5.
- 293 11. Jang EJ, Choe YJ, Kim RK, Park YJ. BNT162b2 Vaccine Effectiveness Against the
- SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years. JAMA pediatrics **2023**.
- 295 12. Kim J, Choe YJ, Jang EJ, et al. Effectiveness of Booster mRNA Vaccines Against SARS-
- 296 CoV-2 Infection in an Elderly Population, South Korea, October 2021-January 2022.
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of
- 298 America **2022**; 75(5): 920-1.
- 299 13. Kim YY, Choe YJ, Kim J, et al. Effectiveness of Second mRNA COVID-19 Booster
- Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents.
- 301 Emerging infectious diseases **2022**; 28(11): 2165-70.
- 302 14. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against
- 303 SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC medicine
- **2022**; 20(1): 200.
- 305 15. Liu B, Stepien S, Qian J, et al. Comparative effectiveness of four COVID-19 vaccines,
- BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against
- 307 SARS-CoV-2 B.1.1.529 (Omicron) infection. medRxiv **2022**: 2022.12.22.22283869.

308 16. Hielscher F, Schmidt T, Klemis V, et al. NVX-CoV2373-induced cellular and humoral 309 immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and 310 mRNA-1273-regimens. Journal of clinical virology: the official publication of the Pan 311 American Society for Clinical Virology **2022**; 157: 105321. 312 17. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults 313 in the United States and Mexico. The New England journal of medicine 2022; 386(6): 314 531-43. 315 18. Rydyznski Moderbacher C, Kim C, Mateus J, et al. NVX-CoV2373 vaccination induces 316 functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. The Journal of 317 clinical investigation **2022**; 132(19). 318 19. Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers 319 neutralization of Omicron sub-lineages. Scientific reports 2023; 13(1): 1222. 320 20. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine 321 against the B.1.351 Variant. The New England journal of medicine 2021; 384(20): 1899-322 909. 323 21. Alves K, Plested JS, Galbiati S, et al. Immunogenicity of a Fourth Homologous Dose of 324 NVX-CoV2373. The New England journal of medicine 2023. 325 22. Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a 326 homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-327 CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The

Lancet Infectious diseases 2022; 22(11): 1565-76.

328

23. Choi MJ, Choi JY, Hyun H, et al. Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals. The Journal of infection **2023**; 86(2): e46-e8.



